LIMN Liminatus Pharma Inc.: מכפיל שווי פעילות להכנסות

High R&D costs and strict FDA oversight create significant barriers for competitors. A team of leading immunologists is retained through stock options, ensuring workforce stability. The EV/Sales history demonstrates the market valuation of revenue excluding debt, where the 0.00 mark serves as a key metric. However, the absence of commercial sales makes the financial stability of Liminatus Pharma (LIMN) entirely dependent on new investments.
liminatuspharma.com - פילוחים אנליטיים ומדדי מפתח (LIMN)

This indicator reflects the total enterprise value relative to sales volume, excluding the impact of debt load to determine an objective market revaluation of the asset. By analyzing the EV/Sales valuation chart, an investor can identify overbought risks, which is critical for Liminatus Pharma (LIMN), whose capitalization relies on the potential of CAR-T therapy against solid tumors and the uniqueness of GCC antigen targeting.